AI assistant
Sending…
Nautilus Biotechnology, Inc. — Director's Dealing 2021
Nov 24, 2021
34183_dirs_2021-11-24_e0078632-66fa-4858-9342-76e6fb7f513a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Nautilus Biotechnology, Inc. (NAUT)
CIK: 0001808805
Period of Report: 2021-11-24
Reporting Person: Mowry Anna (CFO and Treasurer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-11-24 | Common Stock | P | 15000 | $4.5755 | Acquired | 32500 | Direct |
Footnotes
F1: Represents the weighted average share price of an aggregate total of 15,000 shares purchased in the price range of $4.545 to $4.58 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.